RT Journal Article
SR Electronic
T1 Sub-5-minute Detection of SARS-CoV-2 RNA using a Reverse Transcriptase-Free Exponential Amplification Reaction, RTF-EXPAR
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.31.20248236
DO 10.1101/2020.12.31.20248236
A1 Carter, Jake G.
A1 Iturbe, Lorea Orueta
A1 Duprey, Jean-Louis H. A.
A1 Carter, Ian R.
A1 Southern, Craig D.
A1 Rana, Marium
A1 Bosworth, Andrew
A1 Beggs, Andrew D.
A1 Hicks, Matthew R.
A1 Tucker, James H. R.
A1 Dafforn, Timothy R.
YR 2021
UL http://medrxiv.org/content/early/2021/01/04/2020.12.31.20248236.abstract
AB We report a rapid isothermal method for detecting SARS-CoV-2, the virus responsible for COVID-19. The procedure uses a novel reverse transcriptase-free (RTF) approach for converting RNA into DNA, which triggers a rapid amplification using the Exponential Amplification Reaction (EXPAR). Deploying the RNA-to-DNA conversion and amplification stages of the RTF-EXPAR assay in a single step results in the detection of a sample of patient SARS-CoV-2 RNA in under 5 minutes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded by the Midlands Integrative Bioscience Training Partnership funded by the Biotechnology and Bioscience Research Council (BB/R506175/1). There are no other competing interests.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:National Research Ethics Service Committee West Midlands - South Birmingham 2002/201 Amendment Number 4All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data is supplied in the text and supplementary information